A randomised clinical trial investigating the effect of pravastatin versus placebo in men aged 45-64 yr with no history of myocardial infarction and with raised plasma cholesterol levels (LDL cholesterol of at least 155 mg/dL, total cholesterol of at least 252 mg/dL)
Studied treatment | pravastatine 40 mg daily |
Control treatment | placebo |
Concomittant treatment | diet |
Age (mean), yrs | 55 yr |
Women (%) | 0 |
Total cholesterol (mmol/l) | 7.1 mmol/L |
total cholesterol change | 20.0% |
LDL change, end of study (%) | -26% |
HDL change | +5% |
Patients | men aged 45-64 yr with no history of myocardial infarction and with raised plasma cholesterol levels (LDL cholesterol of at least 155 mg/dL, total cholesterol of at least 252 mg/dL) |
Group sizes | 3302 / 3293 |
Inclusion criteria | fasting LDL cholesterol level of at least 155 mg per deciliter during the second and third visits, with at least one value of 174 mg per deciliter or above (4.5 mmol per liter) and one value of 232 mg per deciliter or below (6.0 mmol per liter); no serious ECG abnormalities according to Minnesota code 1 (pathologic Q waves), 4-1, 5-1, or 7-1-1 or arrhythmia such as atrial fibrillation; and no history of myocardial infarction or other serious illness, although men with stable angina who had not been hospitalized within the previous 12 months were eligible |
prior MI or CHD (%) | 5% |
LDL (mmol/l) | 4.99 mmol/L |
HDL (mmol/l) | 1.14 mmol/L |
Triglycerides (mg/dl) | 163 |
Diabetes(%) | 1% |
BMI (kg/m2) | 26 |
Stroke history | NA |
LV hypertrophy | NA |
History of hypertension (%) | 15% |
Blindness | double blind | Inclusion period | Fev 1989 - Sep 1991 |
Follow-up duration | 4.9 years | Centers | multicenter |
Lost to FU | geographical localisation | Scotland | |
Primary endpoint | coronary events (CHD death, MI) | Design | Parallel groups |
PeriodeInclusion | Fev 1989 - Sep 1991 | ||
Hypothese | Superiority |
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-7 [PMID: 7566020] link to pdf add to Mendeley
A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. J Clin Epidemiol 1992;45:849-60 [PMID: 1624967] link to pdf add to Mendeley
Appears in following systematic reviews: